Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer

WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--Incyte Corporation (Nasdaq: INCY) announced today its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of ... Biopharmaceuticals, OncologyIncyte, JANUS 1, ruxolitinib, capecitabine, pancreatic cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news